Cardiology management improves secondary prevention measures among patients with coronary artery disease
P. Michael Ho, MD*,*,
Frederick A. Masoudi, MD, MSPH, FACC ,
Eric D. Peterson, MD, MPH, FACC ,
Gary K. Grunwald, PhD||,
Anne E. Sales, PhD¶,
Karl E. Hammermeister, MD and
John S. Rumsfeld, MD, PhD, FACC
* Health Services Research, Denver, Colorado, USA
Cardiology and Health Services Research, Denver Veteran Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
Cardiology Division, Denver Health Medical Center, Divisions of Cardiology and Geriatric Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
Cardiovascular Outcomes and Quality, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
|| Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado, USA
¶ Ischemic Heart Disease Quality Enhancement Research Initiative (IHD-QUERI), Health Services Research and Development, VA Puget Sound Health Care System, Seattle, Washington, USA
View larger version (9K):
[in a new window]
|
Figure 1 Proportion of coronary artery disease patients meeting low-density lipoprotein (LDL) cholesterol and blood pressure (BP) goals. *p < 0.01. Open bars = no cardiology involvement; solid bars = cardiology involvement.
|
|
View larger version (19K):
[in a new window]
|
Figure 2 Subgroup analysis. BP = blood pressure; DM = diabetes mellitus; LDL = low-density lipoprotein.
|
|
View larger version (13K):
[in a new window]
|
Figure 3 Proportion of coronary artery disease patients with and without cardiology involvement prescribed the following classes of medications. ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blockers; CCB = calcium channel blocker. *p < 0.01. Open bars = no cardiology involvement; solid bars = cardiology involvement.
|
|
|
